Novel Interventions For The Diverse Population Of Australians With Bronchiectasis
Funder
National Health and Medical Research Council
Funding Amount
$726,822.00
Summary
Bronchiectasis is a chronic lung condition in which infection causes wheeze, breathlessness, fatigue and sputum production - markedly reducing quality of life and requiring repeated hospital admissions. Risk of hospitalisation due to the disease is up to 9-fold higher in Indigenous vs other Australians. This research will examine two new, low-cost therapies with excellent potential to treat bronchiectasis: a new antibiotic, Azithromycin, and a mucus-clearance agent, hypertonic saline.